References
Krulich L, Dhariwal A, McCann S: Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83:783, 1968
Brazeau P, Somatostatin: A peptide with unexpected physiologic activities. Am J Med 71(Suppl. 61B):8–13, 1986
Mozell E, Stenzel P, Woltering EA, Rosch J, O'Dorisio TM: Functional Endocrine Tumors of the Pancreas: Clinical Presentation, Diagnosis, and Treatment. St. Louis, MO: Mosby Year Book, 1990
Pollak MN, Polychronakos C, Yousefi S, Richard M: Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells. Biochem Biophys Res Commun 154(1):326–331, 1988
Pollak M, Costantino J, Polychronakos C, Blauer SA, Guyda H, Redmond C, Fisher B, Margolese R: Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. JNCI 82(21):1693–1697, 1990
Williams ST, Woltering EA, O'Dorisio TM, Fletcher WS: Effect of octreotide acetate on pancreatic exocrine function. Am J Surg 157:459–462, 1989
Ellison EC, O'Dorisio TM, Woltering EA, Sparks J, Mekhjian HS, Fromkes JJ, Carey LC: Suppression of gastrin and gastric acid secretion in the Zollinger-Ellison Syndrome by long-acting somatostatin (SMS 201–995). Scand J Gastroenterol 21(Suppl. 119):170–176, 1986
Richards WO, Geer R, O'Dorisio TM, Robarts T, Parish KL, Rice D, Woltering G, Abumrad NN: Octreotide acetate induces fasting small bowel motility in patients with dumping syndrome. J Surg Res 49:483–487, 1990
O'Dorisio MS, Chen F, O'Dorisio TM, Wray D, Qualman SJ: Characterization of somatostatin receptors on human neuroblastoma tumors. Cell Growth and Differentiation 5:1–8, 1994
Mozell EJ, Woltering EA, O'Dorisio TM: Non-endocrine applications of somatostatin and octreotide acetate: facts and flights of fancy. Disease-a-Month 37(12):751–848, 1991
Raynor K, Murphy WA, Coy DH, Taylor JE, Moreau J-P, Yasuda K, Bell GI, Reisine T: Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Molecular Pharmacology 43:838–844, 1993
Raynor K, O'Carroll AM, Kong H, Yasuda K, Mahan LC, Bell GI, Reisine T: Characterization of cloned somatostatin receptors SSTR4 and SSTR5. Molecular Pharmacology 44(2):385–392, 1993
Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WAP, Kooij PPM, Oei HY, van Hagen M, Postema PTE, de Jong M, Reubi JC, Visser TJ, Reijs AEM, Hofland LJ, Koper JW, Lamberts SWJ: Somatostatin receptor scintigraphy with (111ln-DTPA-D-Phe1) and (123l-tyr3)-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 20:716–731, 1993
Scheidhauer K, Hildebrand G, Luyken C, Schomacker S, Klug N, Schicha H: Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences. Horm Metab res 27(Suppl.):59–62, 1993
Hoefnagel CA, Rankin EM, Validesolmos RA, Israelis SP, Pavel S, Janssen AGM: Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamid and indium-111-pentetreotide. Eur J Nucl Med 21:587–588, 1994
Woltering EA, O'Dorisio MS, O'Dorisio TM: The role of radiolabeled somatostatin analogs in the management of cancer patients. PPO Updates 9(8):1–16, 1995
Sharma C, Alperin-Lea RC, Johnson MA, Burleigh BD, Woltering EA: Inhibition of octreotide acetate (OA) on proliferation of porcine coronary artery smooth muscle, endothelium, and fibroblasts cells. FASEB 9(3):(Abstract), 1995
Anthony L, Johnson D, Hande K, Shaff M, Winn S, Krozely M, Oates J: Somatostatin analog Phase I trial in neuroendocrine neoplasms. Acta Oncol 32(2):217–223, 1993
Mozell E, Woltering EA, O'Dorisio TM, Fletcher WS, Sinclair AJ, Hill D: Effect of somatostatin analog on peptide release and tumor growth in the Zollinger-Ellison Syndrome. SG&O 170(6):476–484, 1990
Patel PC, Barrie R, Hill N, Landeck S, Kurozawa D, Woltering EA: Post-receptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surg 116(6):1148–1152, 1994
Barrie R, Woltering EA, Hajarizaheh H, Mueller C, Ure T, Fletcher WS: Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res 55:446–450, 1993
Woltering EA, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J, Fassler J: Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 50:245–251, 1991
Bloom SR, Mortimer CM, Thorner MO et al.: Inhibition of gastrin and gastric acid secretion by growth-hormone release-inhibiting hormone. Lancet 2:1106–1109, 1974
Heisler S, Reisine TD, Hook VYH, Axelrod J: Somatostatin inhibits multireceptor stimulation of cyclic AMP formation and corticotropin secretion in mouse pituitary tumor cells. Proc Natl Acad Sci 79:6502–6506, 1982
French MB, Moor BC, Lussier BT, Kraicer J: Protein kinase-C is not essential for growth hormone (GH)-releasing factor-induced GH release from rat somatotrophs. Endocrinology 124:2235–2244, 1989
Reisine T: Multiple mechanisms of somatostatin inhibition of adrenocorticotropin release from mouse anterior pituitary cells. Endocrinology 116:2259–2266, 1985
Woltering EA: 1995 (UnPub)
Maynes S, Bezos A, Parish C: A novel in vitro assay for human angiogenesis. New Cancer Strategies: Angiogenesis Antagonists (Abstract), 1995
Weber C, Merriam L, Koschitzky T, Karp F, Benson M, Forde K, LoGerfo P: Inhibition of growth of human breast carcinomas in vivo by somatostatin analog SMS 201–995: treatment of nude mouse xenografts. Surg 106:416–422, 1989
Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Bruns C: Somatostatin analog octreotide enhances the antineoplastic effects of tamoxifen and ovarietomy on 7,12-dimethylben-z(a)anthracene-induced rat mammary carcinomas. Cancer Res 54(24):6334–6337, 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Woltering, E.A., Watson, J.C., Alperin-Lea, R.C. et al. Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs 15, 77–86 (1997). https://doi.org/10.1023/A:1005774713202
Issue Date:
DOI: https://doi.org/10.1023/A:1005774713202